keyword
MENU ▼
Read by QxMD icon Read
search

Phpt cinacalcet

keyword
https://www.readbyqxmd.com/read/27873072/cinacalcet-hydrochloride-relieves-hypercalcemia-in-japanese-patients-with-parathyroid-cancer-and-intractable-primary-hyperparathyroidism
#1
Yasuhiro Takeuchi, Shunsuke Takahashi, Daishu Miura, Makoto Katagiri, Noriaki Nakashima, Hiroko Ohishi, Ryutaro Shimazaki, Yoshihiro Tominaga
Pharmacological treatment of hypercalcemia is essential for patients with parathyroid carcinoma and intractable primary hyperparathyroidism (PHPT). Use of the calcimimetic cinacalcet hydrochloride (cinacalcet) is an option to treat such patients. We investigated the efficacy and safety of cinacalcet in Japanese patients with parathyroid carcinoma and intractable PHPT. Five Japanese patients with parathyroid carcinoma and two with intractable PHPT were enrolled in an open-label, single-arm study consisting of titration and maintenance phases...
November 21, 2016: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/27545632/-the-effects-of-cinacalcet-in-renal-stone-formers-with-primary-hyperparathyroidism
#2
Corrado Vitale, Francesca Bermond, Amelia Rodofili, Giorgio Soragna, Cristina Marcuccio, Alberto Tricerri, Martino Marangella
Primary hyperparathyroidism (PHPT) may favor nephrolithiasis mainly through an increase in calcium and phosphate urinary excretion. Cinacalcet exhibits good efficacy to control hypercalcemia in PHPT, but it is not so far known whether it might be a useful tool to prevent stone recurrences. Of 67 patients with PHPT and recurrent nephrolithiasis, 55 underwent parathyroidectomy (PTX) and 12, not eligible to PTX, were prescribed Cinacalcet. All the patients were evaluated for mineral metabolism, including estimation of state of saturation for calcium oxalate (CaOx) and brushite (bsh), both at baseline and after either PTX or Cinacalcet...
July 2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/26102713/9b-05-association-of-plasma-parathyroid-hormone-with-nighttime-blood-pressure-in-primary-hyperparathyroidism-the-eplerenone-in-primary-hyperparathyroidism-trial
#3
N Verheyen, J Wetzel, J Martensen, E Belyavskiy, A Schmidt, C Colantonio, C Catena, M Gaksch, M R Grübler, E Kraigher-Krainer, B Pieske, A Meinitzer, J Rus-Machan, A Fahrleitner-Pammer, S Pilz, A Tomaschitz
OBJECTIVE: High parathyroid hormone (PTH) is a cardiovascular risk factor. Elevated plasma PTH levels are independently linked with high nighttime blood pressure (BP) in hypertensive patients. We therefore investigated the association between PTH and nighttime BP in patients with primary hyperparathyroidism (pHPT). DESIGN AND METHOD: We analyzed patients with pHPT who participated in the "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. Blood sampling was performed after an overnight fast and all laboratory parameters were determined immediately after blood sampling...
June 2015: Journal of Hypertension
https://www.readbyqxmd.com/read/26033088/molecular-and-clinical-aspects-of-the-target-therapy-with-the-calcimimetic-cinacalcet-in-the-treatment-of-parathyroid-tumors
#4
REVIEW
Alessandra Mingione, Chiara Verdelli, Annalisa Terranegra, Laura Soldati, Sabrina Corbetta
Parathyroid tumors are almost invariably associated with parathormone (PTH) hypersecretion resulting in primary (PHPT) or secondary (SHPT) hyperparathyroidism. PHPT is the third most common endocrine disorder with a prevalence of 1-2% in post-menopausal women; SHPT is a major complication of chronic kidney failure, the prevalence of which is increasing. The calciumsensing receptor (CASR) is the key molecule regulating PTH synthesis and release from the parathyroid cells in response to changes in extracellular calcium concentrations...
2015: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/25645432/a-step-towards-cinacalcet-testing-for-the-diagnosis-of-primary-hyperparathyroidism-comparison-with-the-standardized-intravenous-calcium-loading-a-pilot-study
#5
COMPARATIVE STUDY
A Cailleux, P Vuillermet, J P Basuyau, J F Ménard, H Lefebvre, J M Kuhn, G Prévost
OBJECTIVE: A calcium load to suppress parathyroid hormone (PTH) secretion can help to perform the diagnosis in some case of primary hyperparathyroidism (PHPT) with atypical presentation. A similar test with calcimimetic, which avoids hypercalcaemia, would be of interest. Our proof of concept study was conducted to compare firstly the results of a single-dose cinacalcet testing with those of the standardized short-time calcium load in healthy control (HC) and secondly the results of the single-dose cinacalcet testing in HC and in PHPT...
May 2015: Clinical Endocrinology
https://www.readbyqxmd.com/read/25637076/cinacalcet-normalizes-serum-calcium-in-a-double-blind-randomized-placebo-controlled-study-in-patients-with-primary-hyperparathyroidism-with-contraindications-to-surgery
#6
RANDOMIZED CONTROLLED TRIAL
Aliya Khan, John Bilezikian, Henry Bone, Andrey Gurevich, Peter Lakatos, Waldemar Misiorowski, Liudmila Rozhinskaya, Marie-Louise Trotman, Miklós Tóth
OBJECTIVE: Primary hyperparathyroidism (PHPT) is diagnosed by the presence of hypercalcemia and elevated or nonsuppressed parathyroid hormone (PTH) levels. Although surgery is usually curative, some individuals fail or are unable or unwilling to undergo parathyroidectomy. In such individuals, targeted medical therapy may be of value. Cinacalcet normalized calcium level and lowered PTH in patients with PHPT in several phase 2 and open-label studies. We compared cinacalcet and placebo in subjects with PHPT unable to undergo parathyroidectomy...
May 2015: European Journal of Endocrinology
https://www.readbyqxmd.com/read/25631825/transient-hypercortisolism-and-symptomatic-hyperthyroidism-associated-to-primary-hyperparathyroidism-in-an-elderly-patient-case-report-and-literature-review
#7
REVIEW
Chiara Sabbadin, Gabriella Donà, Luciana Bordin, Maurizio Iacobone, Valentina Camozzi, Caterina Mian, Decio Armanini
BACKGROUND: Primary hyperparathyroidism (PHPT) is often found on routine blood tests, at a relatively asymptomatic stage. However many studies suggest different systemic effects related to PHPT, which could be enhanced by an abnormal cortisol release due to chronic stress of hyperparathyroidism. Being PHPT frequently found in the 6(th) to 7(th) decade of life, a careful and multifaceted approach should be taken. CASE PRESENTATION: We report the case of an elderly patient with symptomatic PHPT and incidental pulmonary embolism...
2015: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/25617920/-primary-hyperparathyroidism-new-concepts-new-recommendations
#8
G Crouzeix, V Kerlan
Today, primary hyperparathyroidism (PHPT) is frequently diagnosed at an asymptomatic stage. New international guidelines presented at the Endocrine Society congress update the management of this disease. Normocalcemic PHPT is part of the diagnostic spectrum of PHPT, its natural history is poorly known, and monitoring is proposed once secondary HPT has been eliminated. Bone involvement, classically predominant in cortical bone, also affects trabecular bone. Osteodensitometry is poorly effective at the vertebral level and new methods (trabecular bone score [TBS], vertebral fracture assessment [VFA]) should improve the assessment of the risk of fracture...
October 2014: Annales D'endocrinologie
https://www.readbyqxmd.com/read/25367603/primary-hyperparathyroidism-during-pregnancy
#9
REVIEW
Vincent Dochez, Guillaume Ducarme
PURPOSE: Primary hyperparathyroidism (pHPT) during pregnancy is rare and associated with increased morbidity and mortality for both mother and fetus. This review aims to draw together recent thinking on pregnancy and pHPT. METHODS: We have performed a Pubmed (Medline(®)) search with no time limit using "primary hyperparathyroidism", "pregnancy" or "management" as keywords. We reviewed 37 articles in English and French languages on pHPT characteristics, clinical presentations, pregnancy complications, birth outcomes and management of pHPT during pregnancy...
February 2015: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/25240499/the-primara-study-a-prospective-descriptive-observational-study-to-review-cinacalcet-use-in-patients-with-primary-hyperparathyroidism-in-clinical-practice
#10
MULTICENTER STUDY
P Schwarz, J J Body, J Cáp, L C Hofbauer, M Farouk, A Gessl, J M Kuhn, C Marcocci, C Mattin, M Muñoz Torres, J Payer, A Van De Ven, M Yavropoulou, P Selby
OBJECTIVE: Medical management of primary hyperparathyroidism (PHPT) is important in patients for whom surgery is inappropriate. We aimed to describe clinical profiles of adults with PHPT receiving cinacalcet. DESIGN: A descriptive, prospective, observational study in hospital and specialist care centres. METHODS: For patients with PHPT, aged 23-92 years, starting cinacalcet treatment for the first time, information was collected on dosing pattern, biochemistry and adverse drug reactions (ADRs)...
December 2014: European Journal of Endocrinology
https://www.readbyqxmd.com/read/25162668/medical-management-of-primary-hyperparathyroidism-proceedings-of-the-fourth-international-workshop-on-the-management-of-asymptomatic-primary-hyperparathyroidism
#11
Claudio Marcocci, Jens Bollerslev, Aliya Aziz Khan, Dolores Marie Shoback
OBJECTIVE: Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The only available definitive therapy is parathyroidectomy, which is appropriate to consider in all patients. The purpose of this report is to provide an update on calcium and vitamin D supplementation and medical management for those patients with PHPT who cannot or do not want to undergo surgery. METHODS: Questions were developed by the International Task Force on PHPT. A comprehensive literature search was undertaken, and relevant articles published between 2008 and 2013 were reviewed in detail...
October 2014: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/24285106/impact-of-cinacalcet-hydrochloride-in-clinical-management-of-primary-hyperparathyroidism-in-multiple-endocrine-neoplasia-type-1
#12
COMPARATIVE STUDY
M Del Prete, V Marotta, V Ramundo, F Marciello, A Di Sarno, R Esposito, A C Carratù, C De Luca Di Roseto, C Di Somma, A Colao, A Faggiano
AIM: Primary hyperparathyroidism (PHPT) is one of main cause of morbidity in patients with multiple endocrine neoplasia type 1 (MEN1). Medical therapy with cinacalcet-hydrochloride may modify the therapeutic strategy of MEN1 related PHPT. We present an experience with cinacalcet-hydrochloride in two patients with MEN1 PHPT. METHODS: The study included two MEN1 patients belonging to the same family (a 50-year-old woman and her daughter aged 20 years) with PHPT secondary to multiple involvement of parathyroid glands and other MEN1 related tumors...
December 2013: Minerva Endocrinologica
https://www.readbyqxmd.com/read/23730501/experience-with-cinacalcet-in-primary-hyperparathyroidism-results-after-1-year-of-treatment
#13
Inés Luque-Fernández, Antonia García-Martín, Alessandra Luque-Pazos
OBJECTIVES: To assess the characteristics of patients with primary hyperparathyroidism (PHPT) treated with cinacalcet and to evaluate its efficacy in reducing serum calcium and parathyroid hormone (PTH) concentrations after 1 year of treatment. METHODS: The study included 20 patients with PHPT who had completed at least 12 months of treatment with cinacalcet (eight patients for refusal of parathyroidectomy, three for surgery not possible due to comorbidities and nine for progressive hypercalcemia prior to surgery)...
June 2013: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/23452174/cinacalcet-hydrochloride-for-the-treatment-of-hyperparathyroidism
#14
REVIEW
Nicolas Verheyen, Stefan Pilz, Kathrin Eller, Katharina Kienreich, Astrid Fahrleitner-Pammer, Burkert Pieske, Eberhard Ritz, Andreas Tomaschitz
INTRODUCTION: Effective therapeutic strategies are warranted to reduce the burden of parathyroid hormone excess related morbidity and mortality. The calcimimetic agent cinacalcet hydrochloride is a promising treatment strategy in hyperparathyroidism. AREAS COVERED: This review provides an overview of the pharmacokinetics, clinical efficacy, cost-effectiveness, safety and the efficacy profile of cinacalcet in the setting of primary and secondary hyperparathyroidism (p/sHPT)...
April 2013: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/23228121/cinacalcet-in-the-management-of-primary-hyperparathyroidism-post-marketing-experience-of-an-italian-multicentre-group
#15
MULTICENTER STUDY
Federica Saponaro, Antongiulio Faggiano, Franco Grimaldi, Giorgio Borretta, Maria Luisa Brandi, Salvatore Minisola, Andrea Frasoldati, Enrico Papini, Alfredo Scillitani, Chiara Banti, Michela Del Prete, Fabio Vescini, Laura Gianotti, Loredana Cavalli, Elisabetta Romagnoli, Annamaria Colao, Filomena Cetani, Claudio Marcocci
OBJECTIVE: To report the Italian experience on cinacalcet use following its approval by the European Medical Agency (EMA) to control hypercalcaemia in patients with primary hyperparathyroidism (PHPT). DESIGN: Retrospective data collection from 100 patients with sporadic (sPHPT) and 35 with familial PHPT (fPHPT) followed in eight Italian centres between October 2008 and March 2011. MEASUREMENTS: Albumin-adjusted serum calcium, PTH, 25OHD, daily cinacalcet dose and adverse events were recorded during the follow-up (1-46 months)...
July 2013: Clinical Endocrinology
https://www.readbyqxmd.com/read/23148164/new-perspectives-in-the-management-of-primary-hyperparathyroidism
#16
John Ayuk, Mark S Cooper, Neil J L Gittoes
Primary hyperparathyroidism (PHPT) is a biochemical syndrome caused by the inappropriate or unregulated overproduction of parathyroid hormone, Leading to hypercalcae-mia. It was previously considered a relatively rare disorder, with clinical manifestations dominated by renal and/or bone disease. However, in modern times the diagnosis is most frequently recognized coincidentally on biochemical testing in patients evaluated for unrelated complaints. Parathyroidectomy is the only curative treatment for PHPT, with improved outcomes in symptomatic patients following this procedure...
October 2010: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/23024712/bone-disease-in-primary-hyperparathyrodism
#17
Claudio Marcocci, Luisella Cianferotti, Filomena Cetani
Nowadays, primary hyperparathyroidism (PHPT) is mostly a mild disease. Overt skeletal manifestations are rare but decreased bone mineral density (BMD) can still be demonstrated. Even in mild cases, excess parathyroid hormone (PTH) increases bone turnover leading to bone loss particularly at cortical sites. Conversely, a relative preservation of cancellous bone has been shown by histomorphometric analyses and advanced imaging techniques. An increased fracture rate has been demonstrated in untreated patients with PHPT at peripheral sites and in the spine...
October 2012: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/22577108/men1-related-hyperparathyroidism-response-to-cinacalcet-and-its-relationship-with-the-calcium-sensing-receptor-gene-variant-arg990gly
#18
RANDOMIZED CONTROLLED TRIAL
Marcello Filopanti, Uberta Verga, Federica Ermetici, Luca Olgiati, Cristina Eller-Vainicher, Sabrina Corbetta, Luca Persani, Paolo Beck-Peccoz, Anna Spada
OBJECTIVE: Primary hyperparathyroidism (PHPT) is a challenging problem in type 1 multiple endocrine neoplasia (MEN1) due to the high postsurgery recurrence rate. The aim was to evaluate the efficacy of cinacalcet in MEN1 patients in comparison with patients with sporadic PHPT (sPHPT) and the effect of Arg990Gly calcium-sensing receptor (CASR) polymorphism on the response to treatment. DESIGN: This is a randomized, crossover, double-blind study carried out in the University Hospitals...
August 2012: European Journal of Endocrinology
https://www.readbyqxmd.com/read/22271812/therapeutic-challenges-in-elderly-patients-with-symptomatic-hypercalcaemia-caused-by-primary-hyperparathyroidism
#19
L Jacobs, M M Samson, H J J Verhaar, H L Koek
BACKGROUND: Hypercalcaemia resulting from primary hyperparathyroidism (PHPT) can cause a wide range of symptoms, including cognitive disorders, psychiatric symptoms and muscle weakness. Parathyroid surgery is the only definite cure for PHPT. When surgery is contraindicated or patients decide against it, several non-surgical treatment options are available. OBJECTIVE: To illustrate the treatment options of symptomatic hypercalcaemia caused by PHPT in the elderly and discuss these options in consideration of the available evidence...
January 2012: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/22104762/update-on-the-use-of-cinacalcet-in-the-management-of-primary-hyperparathyroidism
#20
REVIEW
C Marcocci, F Cetani
Cinacalcet is an allosteric modulator of the calcium sensing receptor acting to sensitize this receptor to the extracellular calcium. Cinacalcet has been shown to be effective in reducing or normalizing serum calcium levels in several groups of patients with primary hyperparathyroidism (PHPT), including patients with mild to moderate PHPT, intractable PHPT, and parathyroid carcinoma, and in PHPT as a part of multiple endocrine neoplasia type 1. Cinacalcet slightly reduces PTH levels and has no effects on bone mineral density...
January 2012: Journal of Endocrinological Investigation
keyword
keyword
80279
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"